Investment House LLC Has $12.05 Million Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Investment House LLC reduced its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 4.5% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 65,265 shares of the medical research company’s stock after selling 3,041 shares during the quarter. Investment House LLC owned approximately 0.13% of Charles River Laboratories International worth $12,048,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Virtu Financial LLC acquired a new position in Charles River Laboratories International in the 3rd quarter valued at approximately $601,000. JPMorgan Chase & Co. increased its position in Charles River Laboratories International by 21.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company’s stock valued at $95,086,000 after acquiring an additional 85,759 shares during the period. State Street Corp increased its position in Charles River Laboratories International by 2.0% in the 3rd quarter. State Street Corp now owns 2,130,279 shares of the medical research company’s stock valued at $419,601,000 after acquiring an additional 41,421 shares during the period. Janus Henderson Group PLC increased its position in Charles River Laboratories International by 7.6% in the 3rd quarter. Janus Henderson Group PLC now owns 46,018 shares of the medical research company’s stock valued at $9,064,000 after acquiring an additional 3,268 shares during the period. Finally, Neo Ivy Capital Management acquired a new position in Charles River Laboratories International in the 3rd quarter valued at approximately $966,000. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, CEO James C. Foster acquired 6,075 shares of the company’s stock in a transaction on Thursday, February 20th. The shares were purchased at an average cost of $165.01 per share, with a total value of $1,002,435.75. Following the completion of the purchase, the chief executive officer now owns 183,639 shares of the company’s stock, valued at approximately $30,302,271.39. This represents a 3.42 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Joseph W. Laplume sold 4,400 shares of the firm’s stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $162.50, for a total transaction of $715,000.00. Following the completion of the transaction, the executive vice president now directly owns 20,013 shares in the company, valued at $3,252,112.50. This trade represents a 18.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.30% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on CRL shares. Robert W. Baird decreased their price target on shares of Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating for the company in a research report on Thursday, February 20th. Bank of America reduced their price objective on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a research note on Friday, December 13th. The Goldman Sachs Group reduced their price objective on shares of Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating on the stock in a research note on Thursday, January 23rd. William Blair lowered shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 22nd. Finally, Barclays reduced their price objective on shares of Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating on the stock in a research note on Tuesday, February 18th. One investment analyst has rated the stock with a sell rating, fifteen have issued a hold rating and one has issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $191.31.

Charles River Laboratories International Stock Up 1.1 %

Shares of NYSE CRL opened at $177.02 on Wednesday. The firm has a market cap of $9.05 billion, a PE ratio of 1,180.13, a P/E/G ratio of 4.54 and a beta of 1.45. Charles River Laboratories International, Inc. has a 12-month low of $150.79 and a 12-month high of $274.77. The company’s fifty day simple moving average is $167.21 and its 200 day simple moving average is $184.18. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The business had revenue of $1 billion for the quarter, compared to analyst estimates of $983.63 million. During the same period in the prior year, the firm earned $2.46 earnings per share. Charles River Laboratories International’s revenue was down 1.1% on a year-over-year basis. As a group, sell-side analysts forecast that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).